NCT00006121TerminatedPhase 2
Phase II Study of Oxaliplatin Single Agent in Patients With Metastatic Breast Cancer After Failure of Anthracycline/Taxane Based Chemotherapy
European Organisation for Research and Treatment of Cancer - EORTC20 sites in 7 countries18 target enrollmentStarted: May 2000Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Terminated
- Enrollment
- 18
- Locations
- 20
Study Overview
Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating women who have advanced or metastatic breast cancer that has not responded to previous chemotherapy.
Detailed Description
OBJECTIVES:
- Determine the therapeutic activity of oxaliplatin in patients with advanced or metastatic breast cancer following failure of anthracycline/taxane based chemotherapy.
- Determine objective response, duration of response, and time to progression in these patients when treated with this regimen.
- Determine the acute side effects of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive oxaliplatin IV over 2 hours on day 1. Treatment continues every 3 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 6 weeks until disease progression and then every 3 months for survival.
Study Design
- Study Type
- Interventional
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Study Sites (20)
Loading locations...
Similar Trials
Completed
Phase 2
Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal CancerColorectal CancerNCT00017082Prologue Research International
Completed
Phase 2
Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic CancerPancreatic CancerNCT00004190Alliance for Clinical Trials in Oncology59
Completed
Phase 2
Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung CancerLung CancerNCT00004126University of Chicago38
Completed
Phase 2
Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or StomachGastric CancerEsophageal CancerNCT00004127University of Chicago35
Completed
Phase 2
Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical CancerCervical CancerNCT00005837Gynecologic Oncology Group